T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Becton Dickinson
BDX
|
+$3.46B |
| 2 |
UnitedHealth
UNH
|
+$2.79B |
| 3 |
Salesforce
CRM
|
+$2.38B |
| 4 |
Sherwin-Williams
SHW
|
+$1.41B |
| 5 |
Philip Morris
PM
|
+$1.34B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$4.44B |
| 2 |
Alphabet (Google) Class C
GOOG
|
+$2.97B |
| 3 |
GE Aerospace
GE
|
+$2.3B |
| 4 |
HCA Healthcare
HCA
|
+$2.17B |
| 5 |
American International
AIG
|
+$1.68B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.68% |
| 2 | Healthcare | 19.49% |
| 3 | Consumer Discretionary | 13.07% |
| 4 | Financials | 11.17% |
| 5 | Communication Services | 8.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2751
AST SpaceMobile
ASTS
$21.5B
| $95K | ﹤0.01% |
15,200
-3,700
| -20% | -$29K |
|
|
CEI
2752
DELISTED
Camber Energy, Inc
CEI
| $95K | ﹤0.01% |
4,758
-2,198
| -32% | -$75.1K |
|
2753
Smartbird Inc
BIRD
$30.1M
| $94K | ﹤0.01% |
1,199
+36
| +3% | +$3.63K |
|
2754
Wave Life Sciences
WVE
$1.04B
| $94K | ﹤0.01% |
28,980
-1,002
| -3% | -$1.93K |
|
|
EMKR
2755
DELISTED
Emcore Corp
EMKR
| $94K | ﹤0.01% |
3,060
-742
| -20% | -$25K |
|
|
AGPU
2756
Axe Compute Inc
AGPU
$95.1M
| $93K | ﹤0.01% |
760
| – | – |
|
|
ENZ
2757
DELISTED
Enzo Biochem, Inc.
ENZ
| $93K | ﹤0.01% |
44,800
| – | – |
|
2758
Workhorse Group
WKHS
$34.3M
| $92K | ﹤0.01% |
12
| – | – |
|
|
LYLT
2759
DELISTED
Loyalty Ventures Inc. Common Stock
LYLT
| $92K | ﹤0.01% |
25,854
+757
| +3% | +$8.1K |
|
2760
Angi Inc
ANGI
$187M
| $91K | ﹤0.01% |
1,990
-530
| -21% | -$26K |
|
2761
Aqua Metals
AQMS
$9.78M
| $91K | ﹤0.01% |
559
+106
| +23% | +$20.8K |
|
|
AIM
2762
AIM ImmunoTech
AIM
$7.1M
| $91K | ﹤0.01% |
1,169
| – | – |
|
2763
Alpha Pro Tech
APT
$55.4M
| $90K | ﹤0.01% |
20,100
+700
| +4% | +$2.98K |
|
|
AXDX
2764
DELISTED
Accelerate Diagnostics
AXDX
| $90K | ﹤0.01% |
9,028
+4,573
| +103% | +$40.4K |
|
2765
Quantum-Si Incorporated
QSI
$189M
| $90K | ﹤0.01% |
38,714
-1,171,022
| -97% | -$4.48M |
|
|
GRTS
2766
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $90K | ﹤0.01% |
37,300
-3,799
| -9% | -$9.98K |
|
2767
CEL-SCI Corp
CVM
$25.5M
| $89K | ﹤0.01% |
660
+127
| +24% | +$13.2K |
|
2768
Heron Therapeutics
HRTX
$61.8M
| $89K | ﹤0.01% |
31,768
-1,460
| -4% | -$5.86K |
|
|
BLUE
2769
DELISTED
bluebird bio
BLUE
| $88K | ﹤0.01% |
1,060
+26
| +3% | +$2.02K |
|
2770
Aveanna Healthcare
AVAH
$2.3B
| $87K | ﹤0.01% |
38,518
+11,886
| +45% | +$34.5K |
|
2771
MiMedx Group
MDXG
$609M
| $87K | ﹤0.01% |
24,935
+700
| +3% | +$2.74K |
|
2772
Phathom Pharmaceuticals
PHAT
$730M
| $87K | ﹤0.01% |
+10,340
| New | +$106K |
|
|
LOGC
2773
DELISTED
ContextLogic
LOGC
| $87K | ﹤0.01% |
1,810
-41
| -2% | -$2.22K |
|
|
LICY
2774
DELISTED
Li-Cycle Holdings Corp.
LICY
| $87K | ﹤0.01% |
+1,577
| New | +$92.3K |
|
|
AVDX
2775
DELISTED
AvidXchange
AVDX
| $86K | ﹤0.01% |
+13,989
| New | +$111K |
|
Similar funds
T. Rowe Price Associates's Q2 2022 Portfolio in Review
As of Q2 2022, T. Rowe Price Associates held 3,063 positions worth $791B, down 20% from $992B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
T. Rowe Price Associates's Q2 2022 filing shows 88 new, 1,490 increased, 1,207 reduced and 101 closed positions. Its largest new stake was ESAB: 6,073,363 shares worth $266M. The largest sale was Meta Platforms (Facebook), an estimated $4.44B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 27% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q2 2022 buy was ESAB: 6,073,363 shares worth $266M.
- T. Rowe Price Associates added most to Becton Dickinson in Q2 2022, an estimated $3.46B increase.
- T. Rowe Price Associates's biggest Q2 2022 reduction was Meta Platforms (Facebook), cutting an estimated $4.44B.
- T. Rowe Price Associates fully exited Ortho Clinical Diagnostics Holdings plc Ordinary Shares in Q2 2022, selling an estimated $364M.
- T. Rowe Price Associates's ten largest holdings make up 26% of its $791B portfolio in Q2 2022.
- T. Rowe Price Associates opened 88 new positions and closed 101 in Q2 2022.
- T. Rowe Price Associates's portfolio value fell 20% quarter-over-quarter to $791B.
Based on T. Rowe Price Associates's 13F filing for Q2 2022, filed 15 Aug 2022.